Skip to main content

Advertisement

SpringerLink
Log in

Common medications and prostate cancer mortality: a review

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Most prostate cancer patients also have comorbidities that are treated with both prescription and nonprescription medications; furthermore, many use dietary supplements. We assess their association with prognosis after prostate cancer diagnosis, and we discuss methodological challenges and clinical implications.

Methods

We reviewed high-quality observational studies investigating the association of commonly used medications and supplements with prostate cancer-specific mortality.

Results

There is preliminary evidence that statins and metformin use may be associated with lower risk of cancer-specific mortality after prostate cancer diagnosis; conversely, high calcium and multivitamin supplementation may be associated with increased risk. Evidence is inconclusive for nonsteroidal anti-inflammatory drugs, acetylsalicylic acid (aspirin), insulin, antihypertensives such as angiotensin-converting enzyme inhibitors and beta-blockers, digoxin, and warfarin. Common limitations of the internal validity of studies examined include unmeasured confounding and confounding by indication, competing risks, and time-related biases such as immortal time bias. The majority of studies focused on Caucasian men with specific comorbidities, while heterogeneity among patients and tumors was mostly not assessed.

Conclusions

Commonly prescribed medications and over-the-counter supplements may influence prognosis among prostate cancer patients. Further well-designed pharmacoepidemiologic studies and randomized controlled trials of selected medications in appropriate patient groups are necessary before these drugs can bear new indications for prostate cancer treatment. We discuss considerations when deciding about use of these drugs in clinical practice at the present time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, Penson DF (2013) Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 158(10):709–717. doi:10.7326/0003-4819-158-10-201305210-00005

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673–683. doi:10.1038/nrd1468

    Article  CAS  PubMed  Google Scholar 

  3. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 314(17):1818–1831. doi:10.1001/jama.2015.13766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Neuhouser ML, Kristal AR, Patterson RE, Goodman PJ, Thompson IM (2001) Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutr Cancer 39(1):12–18. doi:10.1207/S15327914nc391_2

    Article  CAS  PubMed  Google Scholar 

  5. Grainger EM, Kim HS, Monk JP, Lemeshow SA, Gong M, Bahnson RR, Clinton SK (2008) Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center. Urol Oncol 26(2):125–132. doi:10.1016/j.urolonc.2007.01.016

    Article  CAS  PubMed  Google Scholar 

  6. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802. doi:10.1056/NEJMoa1201735

    Article  CAS  PubMed  Google Scholar 

  7. Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andren O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR (2016) Cholesterol metabolism and prostate cancer lethality. Cancer Res 76(16):4785–4790. doi:10.1158/0008-5472.CAN-16-0903

    Article  CAS  PubMed  Google Scholar 

  8. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105(6):739–745

    Article  CAS  PubMed  Google Scholar 

  9. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24):1819–1825. doi:10.1093/jnci/djj499

    Article  CAS  PubMed  Google Scholar 

  10. Raval AD, Thakker D, Negi H, Vyas A, Salkini MW (2016) Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2015.58

    Google Scholar 

  11. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L (2014) Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32(1):5–11. doi:10.1200/JCO.2013.49.4757

    Article  PubMed  Google Scholar 

  12. Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW (2015) Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol 1(4):495–504. doi:10.1001/jamaoncol.2015.0829

    Article  PubMed  Google Scholar 

  13. Collaboration Cholesterol Treatment Trialists, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 7(1):e29849. doi:10.1371/journal.pone.0029849

    Article  Google Scholar 

  14. Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314(10):1021–1029. doi:10.1001/jama.2015.10029

    Article  CAS  PubMed  Google Scholar 

  15. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403. doi:10.1002/ijc.24044

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20(6):953–966. doi:10.1016/j.cmet.2014.09.018

    Article  CAS  PubMed  Google Scholar 

  17. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31(25):3069–3075. doi:10.1200/JCO.2012.46.7043

    Article  CAS  PubMed  Google Scholar 

  18. Zanders MM, Vissers PA, van de Poll-Franse LV (2014) Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication? J Clin Oncol 32(7):701. doi:10.1200/JCO.2013.53.5161

    Article  PubMed  Google Scholar 

  19. Margel D, Urbach D, Fleshner N, Austin PC (2014) Reply to M.M.J. Zanders et al. J Clin Oncol 32(7):702. doi:10.1200/JCO.2013.53.8728

    Article  PubMed  Google Scholar 

  20. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev 23(10):2111–2118. doi:10.1158/1055-9965.EPI-14-0056

    Article  CAS  PubMed  Google Scholar 

  21. Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL (2016) Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control 27(1):105–113. doi:10.1007/s10552-015-0687-0

    Article  PubMed  Google Scholar 

  22. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047. doi:10.1016/S1470-2045(08)70235-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14):1099–1106

    Article  CAS  PubMed  Google Scholar 

  24. Patorno E, Garry EM, Patrick AR, Schneeweiss S, Gillet VG, Zorina O, Bartels DB, Seeger JD (2015) Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf 38(3):295–310. doi:10.1007/s40264-015-0280-1

    Article  PubMed  Google Scholar 

  25. Gu Q, Dillon CF, Eberhardt MS, Wright JD, Burt VL (2015) Preventive aspirin and other antiplatelet medication use among U.S. adults aged >/=40 Years: data from the National Health and Nutrition Examination Survey, 2011–2012. Public Health Rep 130(6):643–654

    Article  PubMed  PubMed Central  Google Scholar 

  26. Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y (2003) Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 12(4):315–326. doi:10.1002/pds.755

    Article  PubMed  Google Scholar 

  27. Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30(28):3540–3544. doi:10.1200/JCO.2011.41.0308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2014) Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 65(3):635–641. doi:10.1016/j.eururo.2013.01.007

    Article  CAS  PubMed  Google Scholar 

  29. Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O’Sullivan JM, Powe DG, Murray LJ (2014) Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control 25(1):33–43. doi:10.1007/s10552-013-0306-x

    Article  PubMed  Google Scholar 

  30. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 5(10):1223–1228. doi:10.1158/1940-6207.CAPR-12-0171

    Article  CAS  Google Scholar 

  31. Flahavan EM, Bennett K, Sharp L, Barron TI (2014) A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 25(1):154–159. doi:10.1093/annonc/mdt428

    Article  CAS  PubMed  Google Scholar 

  32. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM (2014) Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol 32(33):3716–3722. doi:10.1200/JCO.2013.54.8875

    Article  CAS  PubMed  Google Scholar 

  33. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O’Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK, investigators S (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 13(5):549–558. doi:10.1016/S1470-2045(12)70088-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, Moshfegh AJ, Sempos CT, Picciano MF (2010) Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 140(4):817–822. doi:10.3945/jn.109.118539

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Giovannucci E, Liu Y, Stampfer MJ, Willett WC (2006) A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 15(2):203–210. doi:10.1158/1055-9965.EPI-05-0586

    Article  CAS  PubMed  Google Scholar 

  36. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Bueno-de-Mesquita HB, Kiemeney L, Tagliabue G, Palli D, Vineis P, Tumino R, Trichopoulou A, Kassapa C, Trichopoulos D, Ardanaz E, Larranaga N, Tormo MJ, Gonzalez CA, Quiros JR, Sanchez MJ, Bingham S, Khaw KT, Manjer J, Berglund G, Stattin P, Hallmans G, Slimani N, Ferrari P, Rinaldi S, Riboli E (2008) Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 98(9):1574–1581. doi:10.1038/sj.bjc.6604331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Rowland GW, Schwartz GG, John EM, Ingles SA (2012) Calcium intake and prostate cancer among African Americans: effect modification by vitamin D receptor calcium absorption genotype. J Bone Miner Res 27(1):187–194. doi:10.1002/jbmr.505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, Betz JM, Sempos CT, Picciano MF (2011) Dietary supplement use in the United States, 2003–2006. J Nutr 141(2):261–266. doi:10.3945/jn.110.133025

    Article  CAS  PubMed  Google Scholar 

  39. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Manson JE, Glynn RJ, Buring JE (2012) Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA 308(18):1871–1880. doi:10.1001/jama.2012.14641

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Stevens VL, McCullough ML, Diver WR, Rodriguez C, Jacobs EJ, Thun MJ, Calle EE (2005) Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 16(6):643–650. doi:10.1007/s10552-005-0384-5

    Article  PubMed  Google Scholar 

  41. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, Leitzmann MF (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99(10):754–764. doi:10.1093/jnci/djk177

    Article  CAS  PubMed  Google Scholar 

  42. Wilson KM, Giovannucci EL, Mucci LA (2012) Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 14(3):365–374. doi:10.1038/aja.2011.142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8(10):893–899

    CAS  PubMed  Google Scholar 

  44. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549–1556. doi:10.1001/jama.2011.1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Assayag J, Pollak MN, Azoulay L (2014) Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. Eur J Cancer 50(16):2838–2845. doi:10.1016/j.ejca.2014.08.006

    Article  CAS  PubMed  Google Scholar 

  46. Cardwell CR, Coleman HG, Murray LJ, O’Sullivan JM, Powe DG (2014) Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Cancer Epidemiol 38(3):279–285. doi:10.1016/j.canep.2014.03.011

    Article  PubMed  Google Scholar 

  47. Cardwell CR, Mc Menamin UC, Hicks BM, Hughes C, Cantwell MM, Murray LJ (2014) Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med 12:28. doi:10.1186/1741-7015-12-28

    Article  PubMed  PubMed Central  Google Scholar 

  48. Flahavan EM, Sharp L, Bennett K, Barron TI (2014) A cohort study of digoxin exposure and mortality in men with prostate cancer. BJU Int 113(2):236–245. doi:10.1111/bju.12287

    Article  CAS  PubMed  Google Scholar 

  49. Tagalakis V, Tamim H, Blostein M, Hanley JA, Kahn SR (2013) Risk of prostate cancer death in long-term users of warfarin: a population-based case-control study. Cancer Causes Control 24(6):1079–1085. doi:10.1007/s10552-013-0185-1

    Article  CAS  PubMed  Google Scholar 

  50. O’Rorke MA, Murray LJ, Hughes CM, Cantwell MM, Cardwell CR (2015) The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink. Cancer Causes Control 26(3):355–366. doi:10.1007/s10552-014-0511-2

    Article  PubMed  Google Scholar 

  51. Walker AM (1996) Confounding by indication. Epidemiology 7(4):335–336

    CAS  PubMed  Google Scholar 

  52. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25(3):329–338. doi:10.1007/s10552-013-0334-6

    Article  PubMed  Google Scholar 

  53. Rider JR (2016) Trouble in paradise: unmeasured confounding in registry-based studies of etiologic factors. Eur Urol 69(5):883–884. doi:10.1016/j.eururo.2015.10.044

    Article  PubMed  Google Scholar 

  54. Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20(4):488–495. doi:10.1097/EDE.0b013e3181a819a1

    Article  PubMed  PubMed Central  Google Scholar 

  55. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35(12):2665–2673. doi:10.2337/dc12-0788

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4):492–499. doi:10.1093/aje/kwm324

    Article  PubMed  Google Scholar 

  57. Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM (2014) A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol 64(10):959–968. doi:10.1016/j.jacc.2014.06.1186

    Article  PubMed  Google Scholar 

  58. Datta M, Schwartz GG (2012) Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 17(9):1171–1179. doi:10.1634/theoncologist.2012-0051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Jorgensen TL, Herrstedt J, Friis S, Hallas J (2012) Polypharmacy and drug use in elderly Danish cancer patients during 1996–2006. J Geriatr Oncol 3(1):33–40. doi:10.1016/j.jgo.2011.09.001

    Article  Google Scholar 

  60. Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10(4):577–581

    Article  CAS  PubMed  Google Scholar 

Download references

Authors’ contribution

Stopsack: project development, data collection, manuscript writing; Greenberg: project development, data collection, manuscript writing; and Mucci: project development, data collection, manuscript writing.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Konrad H. Stopsack

  2. Department of Neurology, Mayo Clinic, Rochester, MN, USA

    Alexandra J. Greenberg

  3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Lorelei A. Mucci

  4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

    Lorelei A. Mucci

Authors
  1. Konrad H. Stopsack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra J. Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorelei A. Mucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konrad H. Stopsack.

Ethics declarations

Conflict of interest

None.

Human and animal rights

As a review, no human or animal subjects were involved in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stopsack, K.H., Greenberg, A.J. & Mucci, L.A. Common medications and prostate cancer mortality: a review. World J Urol 35, 875–882 (2017). https://doi.org/10.1007/s00345-016-1912-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-016-1912-5

Keywords

Search

Navigation